



The 2nd Virtual Global Congress on
Controversies in Ophthalmology
June 24-25, 2022



FRIDAY, JUNE 24, 2022
15:00-15:55 CET



**CONTROVERSIES IN THE MANAGEMENT OF
DIABETIC MACULAR EDEMA**

SATURDAY, JUNE 25, 2022
13:00-14:00 CET



**PEARLS AND PITFALLS IN MANAGING
EXUDATIVE RETINAL DISEASE**

COPHy GLOBAL VIRTUAL CONGRESS 2021

Friday 20th August 2021

15:00–16:00 CEST

FOR NON-US HEALTHCARE PROFESSIONALS ONLY

Controversies, Challenges & Evidence
on the Management of DME

- 15:00 -15:03 **Welcome and Introduction**
Anat Loewenstein (Israel) – Chair
- 15:03 - 15:15 **Expectations and fears of DME patients treated with IV injections**
Audrey Giocanti (France)
- 15:15 – 15:27 **Suitable naïve vs pre-treated DME patients**
Javier Zarranz Ventura (Spain)
- 15:27 – 15:39 **Early switch vs late switch in DME**
Jorge Ruiz Medrano (Spain)
- 15:39 – 15:51 **In the hands of the expert: what do we know about safety management?**
Laurent Kodjikian (France)
- 15:51 – 16:00 **Discussion and Q&A**
Anat Loewenstein (Israel)

DME – Diabetic Macula Edema

This symposium contains promotional material.

Symposium organised and funded by Allergan, an AbbVie company

Materials developed under European central licence

Registration conditions and licenses differ internationally, please refer to your local Summary of Product Characteristics and Prescribing Information

A list of countries with this product/ indication is available from UK_Medinfo@Allergan.com

Adverse events should be reported to your Ministry of Health and local Allergan office



INT-02U-2150073 | June 2021



Allergan

MEDICAL INSTITUTE®

Promoting Excellence in Clinical Practice

Bayer symposium at the Virtual COPHy Global Congress 2022

COPHy

Join us for a series of engaging debates as our expert speakers explore key topics in the management of exudative retinal disease

Pearls and pitfalls in managing exudative retinal disease

Saturday 25 June 2022 | 13:00–14:00 (CEST)

Chair: Dr Baruch Kuppermann

Sessions	Speaker(s)
Welcome and Introductions	Dr Baruch Kuppermann
Is proactive individualised treatment the new standard of care in DME?	Yes: Dr John Kitchens No: Professor Gemmy Cheung
Is real-world experience as important as the pivotal studies in determining a drug's use?	Yes: Mr James Talks No: Dr Patricia Udaondo
Have we arrived at the end of the road for advancements in nAMD treatment?	Yes: Dr Stela Vujosevic No: Dr Aude Ambresin
Live: Panel discussion / audience Q&A	All
Summary of key learnings	Dr Baruch Kuppermann

Learn more about Bayer by
visiting our online channels:



COPHy, Controversies In Ophthalmology. DME, diabetic macular oedema.
nAMD, neovascular age-related macular degeneration.

This symposium is organised and supported by Bayer.

The summary of product characteristics (SmPC) of aflibercept solution for injection as approved by the European Commission for the European Union can be found [here](#). For the product information in other countries, please contact your Bayer representative.

May 2022 | PP-EYL-ALL-0950-1

